Fig. 1 Schematic representing select targeted therapies for which clinical trial results are available in high-grade gliomas. Edited with permission from Lee et al. “current and future directions for Phase II…
Study (reference) Number of patients Treatment arms PFS (months) OS (months) Comments EORTC/NCI [1] 573 RT/TMZ versus RT 6.9 versus 5.0 15 versus 12 RT/TMZ superior to RT alone RTOG…
Fig. 1 A schematic overview on the current molecularly based subgrouping. In addition to the standard treatments, radiotherapy (RT), temozolomide (TMZ), procarbazine, lomustine and vincristine (PCV) or radiochemotherapy, there are trials…
Fig. 19.1 Incidence of invasive head and neck cancer in AYAs (age 15–39), 2000–2011, SEER18, by anatomical site 19.1.1 Incidence Figure 19.2 shows the incidence of head and neck (oropharyngeal;…
Age 15–39 Estimated cases a Incidence rate Estimated deaths Death rate All cancers 1,048,821 37.5 390,579 14.0 Males 383,209 26.8 183,116 12.8 Females 665,612 48.7 207,463 15.2 LDRb 807,768 33.8…
Fig. 17.1 Incidence of renal cell carcinoma by age, sex (left panel), and extent of disease (right panel) at diagnosis, 2000–2011, SEER18. The left panel inset has a log scale…
Fig. 4.1 Incidence of NHL by age, United States SEER, 2000–2011 Fig. 4.2 Incidence of NHL by age and race/ethnicity; United States SEER, 2000–2011 Table 4.1 Incidence of non-Hodgkin lymphoma…
Fig. 11.1 Incidence of ovarian cancer, United States SEER 18 regions, 2000–2011, by histologic type Fig. 11.2 Distribution of ovarian cancer, United States SEER 18 regions, 2000–2011, by histologic type…
Fig. 14.1 Right lateral and top views of the dynamic sequence of gray matter maturation over the cortical surface. The side bar shows a color representation in units of gray…
